Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 239,711
  • Shares Outstanding, K 33,620
  • Annual Sales, $ 52,610 K
  • Annual Income, $ -66,250 K
  • 60-Month Beta 3.54
  • Price/Sales 4.23
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate -0.41
  • Number of Estimates 2
  • High Estimate -0.35
  • Low Estimate -0.47
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +24.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.15 +71.81%
on 07/15/20
7.34 -2.86%
on 08/14/20
+3.01 (+72.85%)
since 07/14/20
3-Month
3.99 +78.70%
on 07/14/20
7.34 -2.86%
on 08/14/20
+1.71 (+31.55%)
since 05/14/20
52-Week
1.41 +405.67%
on 03/16/20
10.00 -28.70%
on 12/02/19
+3.60 (+101.98%)
since 08/14/19

Most Recent Stories

More News
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis

-- First planned PK clinical trial expected to begin during the third quarter of 2020

AQST : 7.13 (+7.70%)
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 83.72% and 137.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

AQST : 7.13 (+7.70%)
Aquestive Therapeutics: 2Q Earnings Snapshot

WARREN, N.J. (AP) _ Aquestive Therapeutics Inc. (AQST) on Tuesday reported a loss of $2.3 million in its second quarter.

AQST : 7.13 (+7.70%)
Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches

Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems,...

AQST : 7.13 (+7.70%)
Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference

Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems,...

AQST : 7.13 (+7.70%)
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AQST : 7.13 (+7.70%)
Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference

Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems,...

AQST : 7.13 (+7.70%)
Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems,...

AQST : 7.13 (+7.70%)
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options

Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.

AQST : 7.13 (+7.70%)
Why Aquestive Therapeutics (AQST) Stock Might be a Great Pick

Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

AQST : 7.13 (+7.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

See More Share

Trade AQST with:

Business Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 7.72
1st Resistance Point 7.42
Last Price 7.13
1st Support Level 6.75
2nd Support Level 6.38

See More

52-Week High 10.00
Last Price 7.13
Fibonacci 61.8% 6.72
Fibonacci 50% 5.70
Fibonacci 38.2% 4.69
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar